Drug-loaded implant for intracranial drug delivery
By designing the fit and protection of hygroscopic swelling drug-loading implants with the dura, the problem of brain damage and insufficient fit caused by traditional intracranial administration methods is solved, and stable and continuous drug delivery is achieved and dura protection.
Patent Information
- Application Number
- CN202411067881.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-22
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-26
AI Technical Summary
Traditional intracranial administration methods are prone to brain damage, and it is difficult to control the administration rate and insufficient fit between the defect repair material and the dura, resulting in secondary damage to the dura.
A drug-loaded implant is designed with hygroscopic expansion and biocompatible, coated with adhesives to fix contact with the dura and contains an expanded layer and a drug-loaded layer, providing a protective layer and a raised structure to enhance adhesion and fit.
It achieves stable and continuous administration on the dura and provides protection for the dura, reducing the risk of brain damage, improving the fit of the dosing and drug delivery efficiency.
Smart Images

Figure CN119015515A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical technology, and in particular to a drug-carrying implant for intracranial drug administration. Background Art
[0002] It has been found in medical clinical practice that intracranial administration can achieve better therapeutic effects in the treatment of brain diseases such as stroke, meningitis, and glioma.
[0003] However, the method of administering drugs directly through the dura mater is likely to cause damage to the brain. The traditional method of administration cannot control the administration rate, and the administration interval is short, which increases the chance of brain damage. At the same time, the traditional skull defect repair material has poor adhesion to the dura mater. Although the skull defect repair titanium mesh in the prior art uses hyaluronic acid as the main component of the anti-adhesive layer to directly contact the dura mater, due to the fixed shape of the titanium mesh, it is easy to cause the bottom layer coated thereunder and the hyaluronic acid to fail to form a stable fit with the dura mater, resulting in gaps in the middle or movement during use, etc., causing secondary damage to the dura mater.
[0004] Application Contents
[0005] In order to solve the above problems, the present application provides a drug-loaded implant, which has good adhesion to the dura mater, enabling the implant to continuously and stably administer drugs on the dura mater, while providing sufficient protection for the dura mater.
[0006] Additional features and advantages of the present application will be partially explained in the following description, and will be apparent to some extent from the description, or can be known by the practice of the present application. The purpose and other advantages of the present application will be realized and obtained by the elements and combinations particularly pointed out in the appended claims of the specification.
[0007] In order to obtain the above advantages and achieve the purpose of the invention, the present application provides a drug-loaded implant, which is used for intracranial drug administration, specifically, drug administration by contacting with the dura mater. A feature of the present application is that the drug-loaded implant can absorb moisture and expand, so that the drug-loaded implant can absorb moisture and expand after entering the skull, increase the volume, and thus eliminate the gap between the implant and the dura mater.
[0008] A feature of the present application is that the side of the drug-loaded implant in contact with the dura mater is coated with an adhesive, so that the drug-loaded implant and the dura mater are relatively fixed. Furthermore, the adhesive is biocompatible and biodegradable, will not produce adverse reactions such as rejection, and will be degraded and metabolized after a long period of time in the skull, and will not have adverse effects on the brain.
[0009] Another feature of the present application is that the drug-loaded implant can also be divided into an expansion layer and a drug-loaded layer in contact with the dura mater, wherein the expansion layer can absorb moisture and expand. After the expansion layer absorbs moisture and expands, it squeezes the drug-loaded layer located below onto the upper surface of the dura mater to make it fit better. At the same time, all drugs are loaded on the drug-loaded layer, which can also better deliver the drugs to the surface of the dura mater.
[0010] One feature of the present application is that the drug-loaded implant is a gel. The gel has good hygroscopic expansion and biocompatibility, will not produce rejection allergic reactions in the brain, and has a certain elasticity, and can be used as a good buffer protection material.
[0011] Another feature of the present application is that the drug-loaded implant further comprises a protective layer disposed away from the dura mater. Specifically, the protective layer is a titanium alloy plate or polyetheretherketone. Meanwhile, the protective layer can also be a soft absorbable material.
[0012] A feature of the present application is that a plurality of protrusions are arranged on the surface of the drug-loaded implant in contact with the dura mater, so that the drug-loaded implant can be well attached to the surface of the dura mater.
[0013] Both the foregoing summary and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the application as claimed. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the description of the embodiments of the present application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.
[0015] Figure 1 Schematic diagram of the structure of the drug-loaded implant. DETAILED DESCRIPTION
[0016] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0017] The present application relates to a drug-loaded implant, which can be used as any drug administration route that requires direct contact with the body surface for treatment. Preferably, the drug-loaded implant provided by the present application is used for intracranial administration, and further, the drug-loaded implant is administered by contacting the dura mater. Preferably, the drug-loaded implant provided by the present application can be used as a repair material for patients with skull defects.
[0018] The drug-loaded implant involved in the present application has the property of hygroscopic expansion. The term "hygroscopic expansion" means that when a solid enters a humid environment, a part of the solid may absorb water molecules or other liquid substances, thereby causing the solid to expand and expose it to greater stress and strain. The drug-loaded implant involved in the present application can be any one or more substances that meet the national or industry standards for surgical implants, including but not limited to YY / T 0640-2016 / ISO 14630:2012 "General Requirements for Passive Surgical Implants" and YY / T 0647-2021 "Special Requirements for Passive Surgical Implants - Breast Implants".
[0019] Preferably, the drug-loaded implant provided in the present application is a gel, which can be purchased commercially. Preferably, the gel is a hydrogel. Further, the gel can be diffusion-controlled dependent, swelling-controlled dependent, and a combination of the two mechanisms. The drug release mechanisms of the diffusion-controlled dependent and swelling-controlled dependent types are described in detail below. Furthermore, the gel can be methacryloyl gelatin (GelMA), hyaluronic acid (HAMA), chondroitin sulfate (CSMA), and sodium alginate (ALMA).
[0020] The drug-carrying function of a drug-carrying implant involved in the present application is mainly to store the drug between the grid or pore size by utilizing the implant micro-grid or porous structure, so that the drug maintains a high concentration locally in the implant. The release mechanism of the drug is based on diffusion, swelling, chemical or other environmental stimulation, etc. In some embodiments, the drug-carrying implant is a hydrogel, and the hydrogel drug release mechanism can be divided into diffusion-controlled dependent type, swelling-controlled dependent type and a combination of the two mechanisms according to the ratio of the grid pore size and the number of grids. Diffusion-controlled drug release occurs in a very short time, ranging from a few hours to dozens of hours; while diffusion-controlled drug release will last for a long time, from a few weeks to a few months. Preferably, the hydrogel drug delivery is a reservoir type or a matrix type, and diffusion-dependent drug release is achieved through the water-containing grid or pores in the hydrogel. It can be understood that the drug release mechanism of implants of other materials besides hydrogels can also refer to hydrogels.
[0021] The drug delivered by the drug-loaded implant involved in the present application can be any drug that can act on the brain. Specifically, the drug delivered by the drug-loaded implant is a neuroprotectant for treating stroke, including but not limited to Y-3 injection and neuroprotective peptide NA-1; the drug delivered by the drug-loaded implant can also be an antibiotic for treating meningitis, including but not limited to vancomycin; the drug delivered by the drug-loaded implant can also be a chemotherapy drug for treating brain glioma, including but not limited to gefitinib.
[0022] The present application relates to a drug-loaded implant with a side in contact with the dura mater coated with an adhesive. The adhesive involved in the present application can be purchased commercially and meets the relevant requirements of ISO 10993 biocompatibility testing, including but not limited to irritation and sensitization tests, blood compatibility, systemic toxicity, physical and chemical tests, cytotoxicity, implantability tests, etc. At the same time, the adhesive involved in the present application can be absorbed by the human body and enter the human body metabolism, and will not cause adverse effects on human health.
[0023] In some embodiments, Figure 1 As shown, a drug-loaded implant 1 involved in the present application may include an expansion layer 3 and a drug-loaded layer 4 in contact with the dura mater, wherein the expansion layer is hygroscopic and expandable. In some embodiments, the expansion layer may be in direct contact with the dura mater, and the drug-loaded layer is disposed above the expansion layer, and the drug is released to the surface of the dura mater through the expansion layer, thereby completing the drug administration process. In order to solve the problem that the implant cannot form a tight fit with the surface of the dura mater after being placed in the skull, the present application adopts the expansion layer to absorb moisture and expand, thereby squeezing the drug-loaded layer so that it fits more closely with the surface of the dura mater, but the degree of expansion needs to be controlled within a certain range to avoid excessive expansion of the expansion layer to damage the dura mater.
[0024] The drug-loaded implant involved in the present application may also include a protective layer 2 arranged away from the dura mater, and the protective layer may be arranged on the surface of the expansion layer 3 away from the dura mater. The protective layer 2 may be any material known to those skilled in the art, and may be some hard materials, replacing the skull to protect the brain, including but not limited to titanium alloy plates or polyetheretherketone or autologous skulls, and the protective layer may also be some soft materials, such as silica gel, etc., which play a certain buffering role against physical impact. Preferably, the protective layer may be a soft material that can be absorbed by the human body, such as absorbable gelatin, collagen, chitosan, cellulose, polylactic acid, polydioxanone (PDO), polyglycolic acid (PGA), etc. Such materials have good biocompatibility and good mechanical properties, but their preparation process will affect the properties of the final protective layer. If the protective layer is prepared by the casting method, it is generally dense, its pore size is not easy to control, and it is difficult to achieve uniform thickness. The protective layer prepared by the additive manufacturing method has controllable microstructure, pore size, and mechanical properties. It can not only meet the mechanical properties required for dura mater repair, but also promote the growth of new tissue and the formation of new blood circulation. It can be degraded and absorbed by the human body and does not need to be removed after administration. An artificial skull can be installed directly on top of the protective layer.
[0025] It is understood that the drug-loaded implant involved in the present application may include one or more layers, including but not limited to the above-mentioned protective layer 2, expansion layer 3, and drug-loaded layer 4, and the relative positions are not limited to the protective layer 2 being arranged on the outermost side, the expansion layer 3 being arranged below, and the drug-loaded layer 4 being arranged below. Each layer may have any thickness or mass. In some embodiments, the multilayer structure may be manufactured by any method, including but not limited to bonding the layers together with an adhesive, or forming them in sequence by coating, or pressing the layers together by hot pressing, etc.
[0026] The present application relates to a drug-loaded implant having a plurality of protrusions on its surface in contact with the dura mater. In some embodiments, the drug-loaded implant comprises a drug-loaded layer 4, which is configured in a protruding shape to increase adhesion to the dura mater, and the drug-loaded layer 4 may be in the form of a microneedle array or in other protruding shapes.
[0027] The technical solution of the present application is further explained below by way of examples, but the present invention is not limited thereby.
[0028] Example
[0029] In order to evaluate and compare the therapeutic effects of drug-loaded implants, skull bone marrow administration, and intravenous administration on acute stroke, the following animal experiments were performed for verification.
[0030] Experimental conditions: SD rats were used as experimental mice, and the animal model adopted the rat focal cerebral ischemia model (PMCAO) by suture embolism. The method was as follows: the common carotid artery and internal carotid artery of the experimental mice were separated, and the external carotid artery was ligated. A small incision was made through the external carotid artery, and the prepared suture was inserted into the common carotid artery and pushed into the internal carotid artery to block the common cerebral artery to prepare the PMCAO model, and the pathological changes of the rat brain tissue were observed.
[0031] Drug selection: PSD95 protein-related inhibitors NA-1 and Y-3 with neuroprotective targets.
[0032] Example 1
[0033] This embodiment 1 provides a drug-loaded implant, wherein the drug-loaded layer is the neuroleptic NA-1. The drug-loaded implant is attached to the dura mater of mice used in the PMCAO model experiment, and the implant is sutured and then rested for observation.
[0034] Example 2
[0035] This embodiment 2 provides a drug-loaded implant, wherein the drug-loaded layer is the neurosuppressant Y-3. The drug-loaded implant is attached to the dura mater of mice used in the PMCAO model experiment, and the implant is sutured and then rested for observation.
[0036] Comparative Example 1
[0037] In this comparative example 1, the neuroleptic inhibitor NA-1 was injected into the skull of mice used in the PMCAO model experiment, and the mice were sutured and rested for observation.
[0038] Comparative Example 2
[0039] In this comparative example 2, the neuroleptic inhibitor NA-1 was subcutaneously injected into the PMCAO model experimental mice, and the mice were rested and observed.
[0040] The experimental mice of the above embodiments and comparative examples were evaluated for drug efficacy at corresponding time points. The evaluation method was mNSS (modified neurological deficit score, the neurological function level was divided into 0-14 points, the lower the score, the more sound the function, 0 points for normal healthy rats, 14 points for the most functionally impaired rats), and the specific scoring criteria were:
[0041] (1) Tail lifting test (maximum = 3 points). Lift the tail of the rat more than 30 cm above the bottom surface and observe the flexion of the forelimbs (1 point for abnormal limbs on the affected side), flexion of the hind limbs (1 point for abnormal limbs on the affected side), and rotation within 30 seconds that deviates from the vertical axis by more than 10° (1 point for abnormal deviation on the affected side). The total score of this item is 3 points;
[0042] (2) Walking on flat ground (normal = 0 points, maximum 3 points). The rats were placed on an open flat ground and allowed to walk freely. Normal walking was scored as 0 points, inability to walk in a straight line was scored as 1 point, turning to the paralyzed side was scored as 2 points, and falling to the paralyzed side was scored as 3 points.
[0043] (3) Balance beam test (normal = 0, maximum 6 points). The rats were placed on a 1.5 cm wide balance beam and allowed to walk freely. Maintaining balance was scored as 0 points, grabbing the edge of the beam was scored as 1 point, holding the beam tightly and one foot slipping off was scored as 2 points, holding the beam tightly and both feet slipping off was scored as 3 points, trying to maintain balance for 20 seconds but still slipping off was scored as 4 points, trying to maintain balance for 10 seconds but still slipping off was scored as 5 points, and not trying to maintain balance and slipping off after less than 10 seconds was scored as 6 points.
[0044] (4) Reflex loss (maximum 2 points): For the auricular reflex, the head shakes when the ear is touched, and for the corneal reflex, the eye blinks when the cornea is gently touched with a cotton ball ... ear is touched, and
[0045] The rat scores of Example 1-2 and Comparative Example 1-2 are shown in Table 1.
[0046] Table 1
[0047] 24h total score 7d Total Rating Example 1 7 5 Example 2 8 5 Comparative Example 1 8 6 Comparative Example 2 11 8
[0048] The above scoring results show that drug-loaded implants and skull bone marrow administration are superior to intravenous administration in both short-term and long-term therapeutic effects, and the therapeutic effect of drug-loaded implants is better than that of skull bone marrow administration.
[0049] The embodiments described above are only used to illustrate the technical solutions of the present application, rather than to limit them. Although the present application has been described in detail with reference to the aforementioned embodiments, a person skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. Such modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present application, and should all be included in the protection scope of the present application.
Claims
1. A drug-loaded implant, characterized in that: The drug-loaded implant is used for intracranial administration, specifically for administration via contact with the dura mater.
2. A drug-loaded implant as claimed in claim 1, characterized in that: The drug-loaded implant is hygroscopic and swellable.
3. The drug-loaded implant according to claim 1, characterized in that: The side of the drug-loaded implant in contact with the dura mater is coated with an adhesive.
4. A drug-loaded implant as claimed in claim 3, characterized in that: The adhesive is biocompatible and biodegradable.
5. The drug-loaded implant according to claim 1, characterized in that: The drug-loaded implant comprises an expansion layer and a drug-loaded layer in contact with the dura mater, wherein the expansion layer is hygroscopic and expandable.
6. A drug-loaded implant according to claim 1 or 5, characterized in that: The drug-loaded implant is a gel.
7. A drug-loaded implant according to claim 1 or 5, characterized in that: The drug loaded implant also includes a protective layer disposed away from the dura mater.
8. The drug-loaded implant according to claim 7, characterized in that: The protective layer is a titanium alloy plate or polyetheretherketone.
9. The drug-loaded implant according to claim 7, characterized in that: The protective layer is made of soft absorbable material.
10. A drug-loaded implant according to claim 1 or 5, characterized in that: A plurality of protrusions are arranged on the surface of the drug-loaded implant in contact with the dura mater.
